Information Provided By:
Fly News Breaks for August 18, 2016
BLUE
Aug 18, 2016 | 09:13 EDT
Goldman analyst Salveen Richter, said bluebird bio is entering a key value inflection point as a more potent Gen2 LentiGlobin is slated to enter the clinic in 2H 2016 in the global pivotal beta-thal with an update at ASH, the unveiling of the CAR T and gene editing programs, and two pivotal update in mid 2017 will result in a transition to commercial focus. Richter rates bluebird bio a Buy with a $135 price target.